Several anti-diabetic agents are available for T2DM treatment.
These treatments differ in their mechanism of drug
action and their long-term outcomes. In addition to these,
non-pharmacological treatments are important, especially
exercise, as it is a major tool to achieve target blood glucose
and HbA1c. Non-glucose beneficial effects can also be obtained.
The many studies reporting the effects of the association
between exercise and oral glucose-lowering drugs
usually focus on attaining better metabolic control. This
study will be conducted to report the glucose variability
and cardiovascular responses at rest, during and after submaximal
exercise under two oral glucose-lowering drugs
(vildagliptin versus glibenclamide).